The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7%-89.3%). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years. K E Y W O R D S biostatistics and bioinformatics, chemotherapy, disease control, hepatitis B virus, infection, reactivation ---
| INTRODUCTION
The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in immunosuppressive therapy. 1, 2 In Japan, 23.2% of blood donors show HBcAb and/or HBsAb-positivity, 1 and HBV reactivation due to immunosuppressive medication use is responsible for 6.8% of all fulminant hepatitis cases. 3 The reactivation of prHBV infection is referred to as de novo hepatitis.
New immunosuppressive therapies have been approved by the Japanese government for entry into the market. Several types have been approved for rheumatic disease treatment. Regarding the risk of HBV reactivation associated with the use of these agents, Japanʼs Pharmaceuticals and Medical Devices Agency 4 issued an alert after several patients died of hepatic failure due to de novo hepatitis. The Japan College of Rheumatology, in collaboration with the Japan Society of Hepatology, published "A proposal for management of rheumatic disease patients with HBV infection receiving immunosuppressive therapy" in 2011, 5 However, the incidence of HBV reactivation among patients with prHBV infection during immunosuppressive therapy for rheumatoid arthritis (RA) is still unclear. Previous cohort studies on the incidence of reactivation were conducted in limited populations. 2 Nowadays, administrative data-based surveys are being conducted for the investigation of the incidences of different diseases. [6] [7] [8] One study that evaluated the incidence and risk factors of de novo used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, in which insurance claim data are comprehensively collected. 9 This study utilized an enormous dataset to detect a rare event, but it had potential limitations. Analyzing the incidence of HBV reactivation among prHBV infection patients using an administrative data set is challenging, as the identification of prHBV infection and HBV reactivation is difficult. There are no diagnostic codes for these two conditions. We aimed to describe the validity of detecting prHBV infection using administrative data through comparisons with chart abstraction because the information of medical charts and database under our organization can be linked to each other, and that allows us to determine the incidence of HBV reactivation during immunosuppressive therapy for RA across Japan.
| MATERIALS AND METHODS

| Study setting
This was a retrospective cohort study. As of April 2018, in the National Hospital Organization (NHO), established in April 2004, there were 141 hospitals including both general acute-care hospitals and specialized long-term care hospitals. All NHO hospitals provide administrative claims data to the Medical Information Analysis (MIA) databank managed by the Clinical Research Center at the NHO Headquarters. The Hepatic Disease Network is one of the clinical networks in the NHO. Four hospitals from this network were included in this study. We chose three hospitals from the western region of Japan and one from the south of Tokyo, as HBV infections are commonly observed in these regions. We excluded patients with human immunodeficiency virus (HIV) infection. We hypothesized that the performance of periodic HBV-DNA testing during immunosuppressive agent administration is indicative of the presence of prHBV infection. Specialist doctors of the Hepatic Disease Network working for the four enrolled NHO hospitals were assumed to have good adherence to the guideline. Using data obtained from the information system of each hospital, patients were divided into those receiving immunosuppressive therapy and those who did not.
| Data extraction
Immunosuppressive agents including methotrexate, leflunomide, tofacitinib, tacrolimus, mizoribine, azathioprine, infliximab, etanercept, tocilizumab, adalimumab, abatacept, golimumab, certolizumab pegol, rituximab, ustekinumab, and secukinumab were usually prescribed for outpatients.
In addition, patients prescribed with NAs were stratified by the timing of NA prescription: before immunosuppressive therapy, after immunosuppressive therapy, and on the same month as the immunosuppressive therapy.
| Chart abstraction
To identify patients with prHBV infection and de novo hepatitis, and 
| Statistical analysis
We calculated the descriptive statistics of the patient characteristics including mean (standard deviation) for continuous variables and proportions for categorical variables. The positive predictive value (PPV) and its exact 95％ confidence interval (CI) of administrative data for the identification of suspected prHBV infection were calculated, considering the chart abstraction result as the reference standard. Using chart abstraction, the annual de novo incidence rates were calculated using the number of de novo hepatitis cases as the numerator and the number of prHBV person-years as the denominator, were determined during the research period. In patients with NA prescription, the chart abstraction results were stratified by the timing of NA prescription in relationship with immunosuppressive therapy. All analyses were performed using SAS 9.4 statistical software (SAS Institute Inc, Cary, NC).
| Ethical approval
The study protocol was approved by the Central Ethics Review Board of the NHO, which waived the need for informed consent from participants (H30-0611039). The study and the opportunity for participants to opt out of it were announced through the website. Although we included study patients simply through administrative data, our result on the incidence rate of de novo hepatitis is similar to that observed in a previous study. Of the 1042 patients in that study, HBV-DNA was detected in 35 (1.93/ 100 person-years). 12 In that study, physicians from 16 Japanese hospitals enrolled patients and observed their information every For the detection of a small number of de novo hepatitis cases using a large database, HBV carriers were excluded even in the absence of diagnostic codes. A previous study assumed that patients who had been prescribed NAs with immunosuppressive therapy in the same month were HBsAg carriers. However, our data indicated that 16 patients (64.0%) who had been prescribed NAs after immunosuppressive therapy were HBsAg carriers.
| RESULTS
| Patient identification and the incidence rate of de novo hepatitis
The de novo incidence rate may be higher among carriers who were vulnerable to reactivation during immunosuppressive therapy.
It might be easy to get contamination when we study without administrative data including blood testing results. A total of 49 carriers were included when we appropriated our algorithm to extract prHBV infection cases. In this study, we were unable to exclude carriers precisely.
The present study has some limitations. First, we did not evaluate the validity of the RA patients' diagnoses. According to our result, 95.1% (329 of 346) of the patients had connective tissue disease and/or rheumatic disease. Moreover, we had already validated the diagnoses with the MIA database in a previous study. 8 As our study included data from only four NHO hospitals, the generalizability of our findings are limited. However, this was a sample study, and there is potential for the performance of a larger study.
A strength of this study was the performance of chart abstraction. Only NHO hospitals can create a link between the database and clinical charts at the patient level in Japan. The present study used hospital information systems for the identification of immunosuppressive agent prescriptions. However, we can extract those subjects from March 2016. We plan to conduct a study on this topic in the future with the use of administrative data as well as electrical medical record data. That study will be larger in scale, allowing for the easy detection of HBV reactivation incidence during immunosuppressive therapy; our technique for the estimation of this incidence rate may be extended to other diseases too.
